BIO-key International (NASDAQ:BKYI) Announces Earnings Results, Beats Expectations By $0.26 EPS

BIO-key International (NASDAQ:BKYI) issued its quarterly earnings data on Thursday. The technology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.26, FiscalAI reports. The company had revenue of $1.92 million during the quarter, compared to the consensus estimate of $1.80 million. BIO-key International had a negative net margin of 60.59% and a negative return on equity of 70.21%.

BIO-key International Price Performance

NASDAQ:BKYI traded up $0.01 during trading hours on Thursday, reaching $3.77. 44,156 shares of the company were exchanged, compared to its average volume of 167,494. The business has a 50 day moving average of $4.37 and a 200 day moving average of $5.27. The company has a market capitalization of $4.11 million, a P/E ratio of -0.68 and a beta of 0.44. BIO-key International has a 1-year low of $3.10 and a 1-year high of $19.70.

Analysts Set New Price Targets

BKYI has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of BIO-key International in a research report on Friday, July 17th. Zacks Research raised shares of BIO-key International to a “hold” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Institutional Trading of BIO-key International

A hedge fund recently raised its position in BIO-key International stock. Geode Capital Management LLC grew its holdings in BIO-key International Inc. (NASDAQ:BKYI) by 49.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 48,892 shares of the technology company’s stock after purchasing an additional 16,271 shares during the period. Geode Capital Management LLC owned approximately 0.45% of BIO-key International worth $26,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 26.51% of the company’s stock.

BIO-key International Company Profile

BIO-key International, Inc is a developer and provider of fingerprint biometric identity and access management solutions, serving enterprise and government customers. The company’s core offerings include a range of fingerprint readers and authentication software designed to verify user identity across physical and digital environments. By leveraging proprietary template-on-card and template-on-device technologies, BIO-key seeks to enhance security and streamline user access without reliance on traditional passwords.

In addition to hardware sensors, BIO-key delivers software platforms that integrate with existing IT infrastructures such as Microsoft Active Directory and major workforce management systems.